Intellect Neurosciences Inc., of New York, reported that a draft pharmacokinetic report from its completed Phase Ib trial for its lead Alzheimer's candidate, OX1, indicated that the drug is rapidly absorbed and distributed in the body after oral administration, the company said, adding that the terminal elimination half-life increased from approximately six to eight hours on the first day of the trial to eight to nine hours on the 14th day.